Article By:
ChinaBio® Today
Saturday, March 16, 2024 2:40 PM EDT
BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug candidates that treat symptoms of schizophrenia.